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Abstract
Background: Prions and amyloid-β (Aβ) oligomers trigger neurodegeneration by hijacking a poorly understood
cellular signal mediated by the prion protein (PrP) at the plasma membrane. In early zebrafish embryos,
PrP-1-dependent signals control cell-cell adhesion via a tyrosine phosphorylation-dependent mechanism.
Results: Here we report that the Src family kinases (SFKs) Fyn and Yes act downstream of PrP-1 to prevent the
endocytosis and degradation of E-cadherin/β-catenin adhesion complexes in vivo. Accordingly, knockdown of
PrP-1 or Fyn/Yes cause similar zebrafish gastrulation phenotypes, whereas Fyn/Yes expression rescues the PrP-1
knockdown phenotype. We also show that zebrafish and mouse PrPs positively regulate the activity of Src kinases
and that these have an unexpected positive effect on E-cadherin-mediated cell adhesion. Interestingly, while PrP
knockdown impairs β-catenin adhesive function, PrP overexpression enhances it, thereby antagonizing its nuclear,
wnt-related signaling activity and disturbing embryonic dorsoventral specification. The ability of mouse PrP to
influence these events in zebrafish embryos requires its neuroprotective, polybasic N-terminus but not its
neurotoxicity-associated central region. Remarkably, human Aβ oligomers up-regulate the PrP-1/SFK/E-cadherin/
β-catenin pathway in zebrafish embryonic cells, mimicking a PrP gain-of-function scenario.
Conclusions: Our gain- and loss-of-function experiments in zebrafish suggest that PrP and SFKs enhance the
cell surface stability of embryonic adherens junctions via the same complex mechanism through which they
over-activate neuroreceptors that trigger synaptic damage. The profound impact of this pathway on early zebrafish
development makes these embryos an ideal model to study the cellular and molecular events affected
by neurotoxic PrP mutations and ligands in vivo. In particular, our finding that human Aβ oligomers activate the
zebrafish PrP/SFK/E-cadherin pathway opens the possibility of using fish embryos to rapidly screen for novel
therapeutic targets and compounds against prion- and Alzheimer's-related neurodegeneration. Altogether, our data
illustrate PrP-dependent signals relevant to embryonic development, neuronal physiology and neurological disease.
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Background
Transmissible neurodegenerative disorders like Creutzfeldt-
Jakob disease and bovine spongiform encephalopathy are
commonly associated with the accumulation of misfolded
prion protein (PrPSc) in the brain. In fact, PrPSc oligomers
can induce neuronal damage in vitro and in vivo [1, 2], and
some of the cellular mechanisms involved have begun to
emerge [3]. On the other hand, expression of the normally
folded protein (PrPC) on the surface of neurons is necessary
for PrPSc to effectively trigger neurodegeneration [4]. More-
over, some PrP mutations cause neurotoxicity in trans-
genic mice and familial prion disease patients even
without inducing PrPSc formation [5, 6]. These observa-
tions strongly suggest that alterations in the function of
PrPC contribute to the early onset of neurodegeneration.
This notion is further supported by the finding that PrPC
transduces neurotoxic signals from Aβ oligomers in
Alzheimer’s patients [7, 8].
Uncovering mechanisms of PrP function in vivo re-
mains a challenging task because no overt phenotypes
are evident in PrP knockout mice, save for subtle abnor-
malities in olfactory physiology, neurogenesis, peripheral
myelination and muscle regeneration [9–13]. Unfortu-
nately, the biochemical basis of these defects and their
connection to prion disease are yet to be established. On
the other hand, in vitro studies have uncovered numer-
ous putative roles for PrPC. Of special interest among
these is the concept of PrPC as a cell surface receptor
and modulator of important signaling molecules like
MAP kinases, PI3K/Akt, PKA, PKC and the SFK member
Fyn [14, 15]. This non-receptor protein tyrosine kinase
has been linked to prion [13, 16–18] and Alzheimer’s
pathologies [19, 20] as well as to the synaptic impairment
caused by binding of Aβ oligomers to PrPC [7]. However,
the physiological relevance of the PrP-Fyn interaction is
unknown, as is the involvement of other SFK members in
PrP-mediated events.
We formerly identified PrP as a positive regulator of
cell-cell adhesion in vivo [21]. Morpholino knockdown
of the zebrafish orthologue PrP-1 in early embryos led to
the down-regulation of E-cadherin and the destabilization
of adherens junctions (AJs). The progressive loss of tissue
integrity in these morphant embryos resulted in gastru-
lation arrest due to their inability to carry out epiboly, an
E-cadherin-dependent morphogenetic cell movement. Im-
portantly, this lethal phenotype was partially rescued by
expression of mouse PrP, highlighting the functional con-
servation among vertebrate PrPs. In the same study, we
showed that PrP-1 engages in homophilic trans-interac-
tions at cell-cell contacts and recruits Fyn to these sites.
We therefore proposed that SFK-related signals mediate
the effect of PrP-1 on embryonic cell adhesion [22].
Due to its anatomical simplicity, the zebrafish gastrula is
ideally suited for biochemical and cell biological analyses
upon genetic or pharmacological manipulations. Here, we
used it to dissect the molecular mechanisms through
which PrP and SFKs modulate embryonic AJ stability
under physiological conditions. We also examined how
this pathway is affected by PrP gain- and loss-of-function,
by exposure to human Aβ oligomers, and by the expres-
sion of mouse PrP mutants with altered neurotoxic or
neuroprotective properties.
Results
PrP-1 regulates the turnover of selected AJ components
During gastrulation, the cell-surface expression of E-
cadherin is dynamically regulated to promote tissue
cohesiveness while allowing for coordinated cell move-
ments [23]. In zebrafish embryos and mammalian cells,
the 120 kDa cell-surface, mature E-cadherin protein is de-
rived from the intracellular cleavage of a 140 kDa precur-
sor polypeptide residing largely in intracellular vesicles
[24, 25]. We reported that PrP-1 knockdown leads to de-
pletion of mature E-cadherin but not its precursor form,
suggesting that biosynthesis of the protein is normal but
either its turnover or maturation are impaired [21]. To
characterize this phenomenon, we first analyzed the
effect of PrP-1 knockdown on E-cadherin internaliza-
tion using immunofluorescence and Western blot.
Treatment of morphant embryos with Dynasore, an
inhibitor of clathrin- and dynamin-dependent endo-
cytosis, restored the cell surface localization of E-
cadherin by 6 hpf (Fig. 1a). In addition, Dynasore in-
duced a concentration-dependent recovery in the
levels of mature E-cadherin (Fig. 1b), indicating that
its depletion in PrP-1 morphants is a consequence of
increased endocytosis. Consistent with these molecular
changes, Dynasore prompted a clear reduction -up to
40.23 %; p < 0.005- in the proportion of arrested/deformed
PrP-1 knockdown embryos (Fig. 1c).
To determine the mechanisms of E-cadherin depletion
in PrP-1 morphants, we treated them with MG-132 and
chloroquine, inhibitors of proteasomal and lysosomal
protein degradation, respectively. By 6 hpf, MG-132 caused
a substantial recovery in the levels of mature E-
cadherin, whereas chloroquine only enhanced the
levels of its 140 kDa precursor form (Fig. 1d). More-
over, MG-132, chloroquine and ammonium chloride
(another lysosomal inhibitor) improved the morph-
ology of knockdown embryos (Fig. 1c), suggesting that
both the mature and precursor forms of E-cadherin con-
tribute to embryonic cell adhesion under these conditions.
Notably, MG-132 -which restores the mature E-cadherin
product- had the strongest rescuing effect of all inhibitors
tested (71.26 % reduction in the proportion of arrested
embryos, Fig. 1c) and restored E-cadherin localization
(Additional file 1: Figure S1B). Together, these expe-
riments indicate that in the absence of PrP-1, mature
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E-cadherin is increasingly endocytosed and degraded via
a proteasome-dependent mechanism.
Binding of β-catenin to the cytoplasmic tail of E-
cadherin helps anchor AJs to the actin cytoskeleton [26].
When detached from E-cadherin, free β-catenin accumu-
lates in the cytosol and is rapidly degraded unless induced
to activate gene transcription in the nucleus [27]. Given
the strong cytosolic localization of β-catenin in PrP-1 mor-
phant gastrulae (Fig. 1a), we examined the stability of this
protein pool. Western blot and immunofluorescence ana-
lyses confirmed that β-catenin is internalized and strongly
down-regulated in these embryos, and that this effect can
be reverted by MG-132 or chloroquine (Fig. 1d and
Additional file 1: Figure S1B). Interestingly, although
β-catenin is not a direct target of the endocytic machinery,
Dynasore treatment also restored its cell surface locali-
zation (Fig. 1a). Because β-catenin associates to the plasma
membrane only indirectly via E-cadherin, this result im-
plies that its internalization and degradation in PrP-1 mor-
phants are secondary effects of E-cadherin endocytosis.
p120-catenin stabilizes E-cadherin at the cell surface
by binding to its cytoplasmic tail and preventing its
Fig. 1 PrP-1 prevents the endocytosis and degradation of AJ components. a. E-cadherin (green) and β-catenin (magenta) localization in 6 hpf
deep cells upon treatment with 10 μM Dynasore (DYNA); MO = lissamine-tagged PrP-1 morpholino (red); scale bar = 10 μm. b and d. Total levels
of E-cadherin and β-catenin at 6 hpf upon treatment with Dynasore, MG-132 and Chloroquine (Chlq). c. Phenotypic analysis upon treatment with
inhibitors. Top: progression of epiboly by 7.5 hpf is assessed by the downward extension of the embryonic margin (arrowheads) relative to the
control (dashed horizontal line); brackets show the thickness of the blastoderm. Bottom: phenotypic quantification. Mean values are shown. e.
AJ protein levels in 6 hpf embryos injected with increasing PrP-1 morpholino doses. WB =Western blot; IF = immunofluorescence. Red and black
arrowheads in 1B, D and E indicate mature E-cadherin (120 kDa) and its more abundant precursor form (140 kDa), respectively. Densitometric
analysis of Western blot bands is expressed in arbitrary units (AU) in B, D and E; average values of three independent experiments ± SEM are
shown; statistical significance was assessed using unpaired, two-tailed t-tests; ns = not significant (p > 0.05), * = p≤ 0.05, ** = p≤ 0.01. In (e),
E-cadherin and β-catenin levels were significantly reduced (p≤ 0.05) at all three morpholino concentrations; p120ctn levels were not significantly
changed at any morpholino dose (p > 0.05). See also Additional file 1: Figure S1
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endocytosis [26]. Since p120-catenin depletion leads to
the internalization and degradation of the entire AJ
complexes, [28], we asked if its levels were reduced in
PrP-1 morphants. Interestingly, Western blot revealed
that while E-cadherin and β-catenin became increasingly
degraded at higher PrP-1 morpholino doses, the levels
of p120-catenin remained unaltered (Fig. 1e). Taken
together, these data show that, in vivo, PrP-1 prevents
the internalization and proteasomal/lysosomal degrad-
ation of E-cadherin/β-catenin complexes independently of
p120-catenin.
Fyn and Yes act downstream of PrP-1 to maintain
embryonic AJ stability
PrP activates Fyn under diverse experimental conditions
including cross-linking of PrP via antibodies as well as
binding of PrP to other PrP molecules, NCAM or Aβ
oligomers [7, 14, 21, 29]. In agreement with these data,
we previously observed the accumulation of zebrafish
embryonic Fyn at PrP-dependent cell-cell contacts [21].
On the other hand, genetic or chemical inactivation of
Fyn and the related SFK Yes have been shown to impair
zebrafish gastrulation [30–32]. Given the common in-
volvement of SFKs in PrP signaling, zebrafish gastrulation,
and the modulation of cadherin-based cell adhesion [33],
we examined whether Fyn and Yes jointly mediate the
effect of PrP-1 on AJs in vivo. First, we assessed the extent
of the similarities between SFK and PrP loss-of-function
phenotypes. At 6 hpf, Fyn and Yes single morphants
showed epibolic arrest and deformed blastoderms (55–
60 % of injected embryos), clearly resembling the PrP-1
morphant phenotype (Fig. 2a and b). The combined Fyn/
Yes knockdown produced a stronger effect than the single
knockdowns (82 % of injected embryos, Fig. 2a and b), in-
dicating functional synergy between the two kinases. The
protein knockdowns were titrated and verified by Western
blot using an anti-Src antibody against the conserved C-
terminus of SFKs (Fig. 3b): morphant embryos showed a
clear reduction in the 65 and 50 kDa bands representing
zebrafish Src/Yes and Fyn, respectively [34] (Fig. 3b). In
line with the phenotypic quantifications, SFK down-
regulation was more pronounced upon combined Fyn/Yes
knockdown. We then asked whether the morphological
resemblance between SFK and PrP-1 morphants involved
common defects in AJ function. In fact, intracellular accu-
mulation of E-cadherin and β-catenin was evident in Fyn
and Yes, single and double knockdown embryos (Fig. 3a
and Additional file 1: Figure S2A). Furthermore, Fyn/Yes
morphant embryos displayed reduced levels of mature
E-cadherin and β-catenin at 6 hpf (Fig. 3c). Hence,
the morphological and molecular convergence of Fyn/
Yes and PrP-1 knockdown phenotypes suggests that
these proteins act cooperatively to stabilize embryonic
AJ components.
Because SFKs transduce extracellular signals from
trans-membrane receptors and GPI-anchored molecules
like PrP [35, 36], we verified whether zebrafish Fyn
and Yes are downstream effectors of PrP-1 and could
Fig. 2 Fyn and Yes act downstream of PrP-1 during epiboly. a. 7.5 hpf embryos injected with different morpholinos or co-injected with PrP-1
morpholino and WT or CA Fyn/Yes EGFP mRNAs. Transmission and fluorescence images are shown merged (morpholinos in red). Expression of
WT or CA Fyn/Yes-EGFP (green) is displayed separately on the lower right. Arrowheads and dashed horizontal line as in Fig. 1c. b. Corresponding
quantification of embryonic phenotypes at 7.5 hpf. Mean values are shown. c. Expression pattern of WT or CA Fyn- and Yes-EGFP in deep cells of
7.5 hpf PrP-1 morphants. Scale bar = 10 μM
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therefore rescue the PrP-1 knockdown phenotype. We
tested for this genetic interaction by co-injecting zeb-
rafish Fyn and Yes EGFP-tagged mRNAs into PrP-1
morphants. To assess if the rescues were directly re-
lated to SFK enzymatic activity, we used wild-type
(WT) and constitutively active (CA) forms of Fyn and
Yes, the latter exhibiting higher kinase activity due to
mutation of the conserved negative regulatory site at
tyrosine (Tyr) 527. After verifying the proper localization
and expression levels of the SFK constructs (Figs. 2c and
3d), their rescuing ability was quantified by scoring em-
bryonic phenotypes between 6 and 7.5 hpf (Fig. 2a and b).
Co-injection of Fyn/Yes mRNAs at 75 pg/embryo signifi-
cantly reduced the proportion of arrested/deformed mor-
phant embryos (41 % reduction, p < 0.01). Notably, CA
Fyn/Yes mRNAs produced a more efficient rescue of the
PrP-1 phenotype (64 % reduction; p < 0.01) using less
mRNA (6 pg/embryo) (Fig. 2b). The higher enzymatic ac-
tivity of the CA constructs was confirmed by Western blot
using phospho-specific antibodies against activated SFKs
(phosphorylated at Tyr416) and their target residue on β-
catenin (phosphorylated at Tyr142) [37]. These Western
blots show that the depletion of phospho-β-catenin in
PrP-1 morphants is reversed upon expression of increas-
ingly active WT and CA Fyn/Yes (Fig. 3d). Finally, we
verified if SFK expression induced the recovery of AJ com-
ponents in PrP-1 morphant embryos. Indeed, exogenous
Fyn and Yes restored the cell surface localization and
levels of E-cadherin and β-catenin by 6 hpf (Fig. 3a and b).
Altogether, these data indicate that Fyn and Yes act
downstream of PrP-1 to promote AJ function via tyrosine
phosphorylation.
Fig. 3 PrP-1 regulates AJs via Fyn and Yes. a. Localization of AJ components (immunofluorescence) in deep (top) and EVL cells (bottom) of 6 hpf
PrP-1, Fyn/Yes morphants or PrP-1 morphants co-injected with Fyn/Yes mRNAs. Scale bars = 10 μM. See also Additional file 1: Figure S2. b. Reduction
in Src/Yes (65 kDa) and Fyn (50 kDa) total levels in 6 hpf Fyn and Yes single or double knockdowns. c, d. Levels of AJ components in 6 hpf embryo
lysates. Activated WT or CA Fyn- and Yes-EGFP were detected with an anti-phospho-Y416 Src antibody. E-cadherin arrowheads as in Fig. 1. WB =Western
blot. Densitometric analysis of Western blot bands is expressed in arbitrary units (AU) in b, c and d; average values of three independent
experiments ± SEM are shown; statistical significance was assessed using unpaired, two-tailed t-tests; ns = not significant (p > 0.05), * = p≤ 0.05,
** = p≤ 0.01, *** = p≤ 0.001
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PrP-1 modulates embryonic SFK function
Having identified Fyn and Yes as downstream effectors
of PrP-1 in vivo, we next asked whether PrP modulates
the levels and activity of SFKs. In fact, Western blots of
6 hpf embryos showed reduced levels of Src/Yes (65 kDa
band, 29.77 % reduction; p < 0.05) and Fyn (50 kDa
band, 43.36 % reduction; p < 0.05) upon PrP-1 knock-
down (Fig. 4a and b). This effect, also evident in whole
mount immunostainings (Fig. 4e), became more pro-
nounced at higher morpholino doses (Additional file 1:
Figure S3A) and could be partially rescued with chlo-
roquine but not with MG-132 (Fig. 4d). Interestingly,
PrP-1 knockdown and chloroquine also modified the
levels of phospho-Tyr142-β-catenin, suggesting that PrP-1
effectively modulates SFK catalytic activity. To verify this,
we measured the ratios of active and non-active SFKs in
PrP-1 morphants. Using phospho-specific antibodies, we
found a significant decline in the ratios of active (phos-
phorylated at Tyr416) vs. total Src/Yes and Fyn (44.28 %
and 83.29 % reduction, respectively; p < 0.01) upon PrP-1
knockdown (Fig. 4c). Notably, no significant changes were
observed in the ratios of inactive (phosphorylated at
Tyr527) vs. total Src/Yes and Fyn (Additional file 1: Figure
S3B), indicating that PrP-1 preferentially stabilizes the
levels of activated SFKs. Accordingly, overall tyrosine
phosphorylation was reduced in the deep cells of PrP-1
morphants (Additional file 1: Figure S3C). Therefore, our
experiments show that PrP-1 positively modulates the
Fig. 4 PrP-1 modulates SFK levels and activation. a-c. Levels of total and activated (phosphor-Y416) SFKs in 6 hpf embryos (a), and densitometric
analysis of Western blot bands (b and c). Phospho-SFK values were normalized to those of total SFKs. Average values ± SEM of four independent
experiments are shown. d. SFK levels in 6 hpf embryos upon PrP-1 knockdown and additional treatment with degradation inhibitors. e. SFK
localization in deep (top) and EVL cells (bottom) of 6 hpf embryos. WB =Western blot; IF = immunofluorescence. Scale bar = 10 μM. Densitometric
analysis of Western blot bands (b, c and d) is expressed in arbitrary units (AU); average values of four independent experiments ± SEM are shown;
statistical significance was assessed using unpaired, two-tailed t-tests; ns = not significant (p > 0.05), * = p ≤ 0.05, ** = p≤ 0.01. See also Additional
file 1: Figure S3
Sempou et al. Molecular Neurodegeneration 2016, 10: Page 6 of 19
http://www.molecularneurodegeneration.com/content/10/1/
levels and activity of SFKs in the gastrula, partly by pre-
venting their lysosomal degradation.
Embryonic PrP gain-of-function phenotype
We have reported that PrP overexpression in zebrafish
induces a distinct morphological phenotype character-
ized by asymmetric epiboly and increased cell-cell adhe-
sion [21, 38]. To mechanistically link the zebrafish PrP
gain- and loss-of-function phenotypes, we characterized
PrP-overexpressing (PrP-OE) embryos at the cellular and
molecular levels. Normally, between 5 and 6 hpf, cellular
structures known as the germ ring and the shield define
the marginal and dorsal regions of the zebrafish gastrula,
respectively [39]. PrP-OE embryos lack these morpho-
logical features and develop instead a large dorsal thicken-
ing (Fig. 5a). This abnormal accumulation of cells results
in mechanical stress and bursting of the embryo before
completion of epiboly (Additional file 2: Video S1). We
reasoned that if PrP-1 knockdown destabilizes AJ compo-
nents, PrP overexpression would enhance their cell sur-
face expression and lead to the observed cell
clumping. In fact, embryos overexpressing mouse PrP
showed normal plasma membrane localization of E-
cadherin and β-catenin at 6 hpf (Additional file 1:
Figure S5A). Surprisingly, while their levels of mature
E-cadherin were increased (Fig. 5b), those of β-catenin
were strongly reduced and could not be restored with
MG-132 or chloroquine (Fig. 5c). Given the asymmetric
deformation of these embryos, we asked if the opposite
changes in the levels of E-cadherin and β-catenin might
stem from local alterations in their distribution along em-
bryonic axes. Whole mount immunostainings of 6 hpf
control embryos revealed an increasing, ventral to dorsal
gradient of both proteins (fluorescence profiles in Fig. 5d).
In contrast, embryos overexpressing mouse or zebrafish
PrPs exhibited increased dorsal E-cadherin accumulation
and reduced dorsal β-catenin (Fig. 5d and Additional file
1: Figure S5B). Concomitant with these alterations, dorsal
cells appeared deformed and enlarged (Fig. 5e). Thus, cell
surface E-cadherin becomes locally up-regulated in the
dorsal cells of PrP-OE embryos, whereas the associated β-
catenin is down-regulated via a mechanism other than
protein degradation.
Crucially, β-catenin signaling is pivotal to dorsal specifi-
cation. As early as the 128-cell stage (2.25 hpf), cytosolic
β-catenin enters the nuclei of a small group of marginal
blastomeres to activate the transcription of dorsalizing
genes [40]. Given the lack of shield and reduced levels of
dorsal β-catenin in 6 hpf PrP-OE embryos, we considered
the possibility that PrP might disturb earlier stages of axis
formation by locally depleting dorsal nuclear β-catenin.
Indeed, quantitative confocal analysis of dorsal marginal
blastomeres at 3 hpf showed a clear reduction in the aver-
age number of cells stained for nuclear β-catenin, from ~7
in control embryos to ~1.8 and ~2.5 in embryos overex-
pressing zebrafish PrP-1 or mouse PrP, respectively (Fig. 6a
and b; p < 0.001). Therefore, the dorsalizing nuclear func-
tion of β-catenin in these early embryos is compromised
as a result of increased PrP activity.
In mouse embryonic stem cells, cell surface E-
cadherin can bind and sequester β-catenin at the plasma
membrane, thus preventing its internalization and nu-
clear translocation [27]. Given the dorsally increased
levels of cell surface E-cadherin in 6 hpf PrP-OE em-
bryos, we examined if a similar mechanism could induce
the observed reduction of dorsal nuclear β-catenin earl-
ier, at 3 hpf. Fittingly, Western blot analysis of 3 hpf
PrP-OE embryos revealed a ~60 % increase in the levels
of mature, cell surface E-cadherin (Fig. 6c). Moreover,
fluorescence measurements indicated that the ratio of
plasma membrane vs. cytosolic β-catenin was 1.8 times
higher in the dorsal cells of PrP-OE embryos than in
their control counterparts (Fig. 6d). This difference was
not due to cytosolic degradation of β-catenin, as control
and PrP-OE embryos showed comparable levels of this
protein at 3 hpf (Fig. 6c). Rather, the increased
plasma membrane localization suggests that β-catenin
is retained by cell surface E-cadherin, thus reducing
the pool of cytosolic molecules available for transloca-
tion to the nucleus.
It is well-established that preventing the nuclear
localization of β-catenin in dorsal blastomeres produces
ventralized embryos by 1 dpf [41]. This effect could only
rarely be observed in PrP-OE embryos because they died
from excessive cell adhesion before completing gastrula-
tion. We circumvented this problem by microinjecting
lower mRNA amounts to overexpress PrP at sub-lethal
levels. The resulting PrP hypomorphic embryos com-
pleted epiboly and by 1 dpf presented a distribution of
ventralized phenotypes with variable penetrance and
expressivity (Fig. 6e). The anterior and dorsal defects
varied in strength, ranging from mildly reduced eyes,
brain and notochord to completely undifferentiated
heads and shortened anterior-posterior axes. This result
further supports the notion that PrP overexpression
impairs the role of β-catenin in axis formation by ex-
acerbating its adhesive function.
Finally we asked if, consistent with the PrP-1 knock-
down data, SFKs also mediate the PrP gain-of-function
phenotype. In fact, at 3 hpf, the relative levels of activated
(p-Tyr416) Src/Yes and Fyn were elevated in PrP-OE
embryos (Fig. 6c). This higher SFK activity was further
evident from the corresponding increase in the levels of
p-Tyr142-β-catenin (Fig. 6c). Moreover, blocking SFK
activity with the pharmacological inhibitor PP2 reduced
the proportion of 6 hpf PrP-OE embryos with abnormal
morphology from 83.26 % to 49.97 % (Fig. 6f; p < 0.01). To
ascertain whether this early increase in SFK activity may
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contribute to the dorsal accumulation of cell surface
E-cadherin, we analyzed their distribution along em-
bryonic axes. Confocal analyses of whole untreated
embryos at 3 hpf revealed that SFKs and E-cadherin
are similarly distributed in a ventral to dorsal gradient
(Additional file 1: Figure S5C). Interestingly, this gradient
was more pronounced in PrP-OE embryos, suggesting
that exogenous PrP enhances E-cadherin adhesion prefer-
entially in dorsal blastomeres by activating their already
higher levels of SFKs. Of note, the conserved link between
PrP and SFK activation was also observed in human
MCF-7 cells, where expression of mouse or fish PrPs
Fig. 5 Morphological and molecular phenotypes upon PrP overexpression. a. Shield formation (red arrowhead) in 6 hpf embryos. See also
Additional file 2: Video S1. b. Levels of E-cadherin, β-catenin and SFKs in 6 hpf embryos expressing mouse PrP. E-cadherin arrowheads as in Fig. 1.
c. Effect of protein degradation inhibitors on the β-catenin levels of PrP-OE embryos. d. Dorsoventral distribution of AJ molecules upon PrP
overexpression. Lateral views (midsections) of whole 6 hpf embryos, along with fluorescence profiles through the dorsoventral axis (indicated by
red arrows; V = ventral, D = dorsal). See also Additional file 1: Figures S4 and S6. e. Close-up from (d) showing aberrant morphology of dorsal deep
cells expressing mouse PrP. WB =Western blot; IF = immunofluorescence. Densitometric analysis of Western blot bands (b and c) is expressed in
arbitrary units (AU); average values of four experiments ± SEM are shown; statistical significance was assessed using unpaired, two-tailed t-tests;
ns = not significant (p > 0.05), * = p≤ 0.05
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triggered the accumulation of SFKs at contacts sites and
the corresponding increase in SFK activity (Additional
file 1: Figure S6). Altogether, our data point at the posi-
tive regulation of SFK activity and AJ function by PrP as
the underlying mechanism behind the zebrafish PrP gain-
and loss-of-function phenotypes.
Functionality of mouse PrP mutants in zebrafish embryos
Deletions in the central region (ΔCR, residues 105-125)
and the N-terminal polybasic stretch (Δ23-31) of mouse
PrP (Fig. 7a) modulate its neurotoxic activities. For
instance, PrPΔCR triggers a lethal neurodegenerative
phenotype in transgenic mice [42] whereas PrPΔ23-31
abrogates this neurotoxic effect as well as the rescuing
(neuroprotective) activity of WT PrP [43–45]. Because
mouse PrP can partially revert the zebrafish PrP-1
knockdown phenotype [21, 38], we used mRNA rescue
experiments to assess whether the ΔCR and Δ23-31 mu-
tations modify the conserved PrP function required for
zebrafish epiboly. After verifying and titrating expression
of the mouse constructs in zebrafish embryos (Fig. 7b),
mRNAs and PrP-1 morpholinos were co-injected into
fertilized eggs, and the resulting phenotypes were scored
at 6 hpf (Fig. 7c). Notably, PrPΔCR retained full activity
and rescued the PrP-1 morphants as efficiently as WT
PrP. In contrast, PrPΔ23-31 showed a strongly reduced
rescuing activity (~74 % relative to WT PrP), similar to
an additional mutant carrying both deletions, PrPΔCR/
Δ23-31. The reduced activity of the Δ23-31-contanining
constructs was not due to deficient cell surface expres-
sion, as demonstrated by whole-mount immunofluores-
cence (Fig. 7d).
Fig. 6 PrP overexpression up-regulates E-cadherin, inhibits nuclear β-catenin and produces ventralized embryos. a. Localization of β-catenin in
the nuclei of dorsal marginal blastomeres at 3 hpf (immunofluorescence). Arrowheads indicate β-catenin-positive nuclei. Scale bar = 20 μm.
b. Quantification of cells with nuclear β-catenin in 3 hpf embryos expressing zebrafish and mouse WT PrP constructs. Average numbers of cells
with nuclear β-catenin per embryo ± SEM are shown (n = 10, three independent experiments); statistical significance was assessed using unpaired,
two-tailed t-tests; *** = p≤ 0.001. c. Levels of E-cadherin, β-catenin and SFKs in 3 hpf embryos expressing mouse PrP (Western blot and densitometric
analysis). E-cadherin arrowheads as in Fig. 1. Densitometric analysis of Western blot bands expressed in arbitrary units (AU); average values of three
independent experiments ± SEM are shown; statistical significance was assessed using unpaired, two-tailed t-tests; ns = not significant (p > 0.05),
* = p≤ 0.05, ** = p≤ 0.01. d. Ratios of plasma membrane to cytosolic β-catenin immunofluorescence in dorsal blastomeres of 3 hpf embryos. Mean
ratios ± SEM are from 10 cells/embryo (n= 7, three independent experiments); statistical significance assessed by unpaired, two-tailed t-test, *** = p< 0.001.
e. Ventralized hypomorphic phenotypes (v1-3) of 1 dpf embryos injected with 20 ng/μl mouse PrP mRNA. f. Quantification of 6 hpf embryos with
abnormal dorsoventral specification upon injection of mouse PrP alone, together with PP2, or with its inactive analog PP3
Sempou et al. Molecular Neurodegeneration 2016, 10: Page 9 of 19
http://www.molecularneurodegeneration.com/content/10/1/
Fig. 7 (See legend on next page.)
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To confirm the rescue data without the confounding
effect of the PrP-1 knockdown phenotype, we also con-
ducted gain-of-function experiments and measured the
ability of the mutants to induce the conserved PrP over-
expression phenotype (Fig. 7e). In these assays, the activity
of the ΔCR construct was again comparable to that of
WT PrP (~95 % of embryos with overexpression phe-
notype), whereas deletion of residues 23-31 reduced this
effect by ~50 % (Fig. 7f). Importantly, these results reflect
the ability of the constructs to inhibit nuclear β-catenin
signaling (Additional file 1: Figure S7), as expression of
WT and ΔCR PrPs significantly reduced the numbers of
marginal blastomeres positive for nuclear β-catenin (2.5
and 3.7 cells/embryo, respectively, vs. 7 cells/untreated
embryo). Moreover, β-catenin nuclear translocation was
barely affected by overexpression of Δ23-31 or Δ23-31/
ΔCR PrPs (7.8 and 7.7 cells/embryo, respectively). There-
fore, we conclude that the N-terminal polybasic stretch
(residues 23-31) is critical for the control of embryonic
cell adhesion by PrP, and that the ΔCR mutation does not
significantly impair this PrP function.
Importantly, expression of mouse PrPΔCR in the pres-
ence or absence of endogenous PrP-1 did not cause
enhanced toxicity or lethality in fish embryos. A possible
explanation is that ΔCR toxicity requires the expression
of a developmentally regulated PrP partner absent from
the zebrafish gastrula. Alternatively, ΔCR toxicity might
be a specific property of mammalian PrPs. To address
this issue, we asked whether zebrafish PrPΔCRs can in-
duce toxicity in an established mammalian cell model.
For this, we generated ΔCR versions of zebrafish PrP-1
and -2 (Additional file 1: Figure S4), and tested them in
HEK cells using the drug-based cellular assay (DBCA)
[46]; changes in cell viability were assessed by the MTT
assay. Notably, cells expressing either zebrafish or
mouse PrPΔCRs were less viable than those express-
ing the corresponding WT PrPs (Fig. 7g; 20 %, 40 %
and 45 % reduction in MTT metabolic activity for
PrP-1-, PrP-2- and mouse PrP-expressing cells; p <
0.05, p = 0.01, and p = 0.01, respectively). This suggests
that the role of the central region as a suppressor of
cytotoxicity is evolutionarily conserved and that the
corresponding toxic cascade in zebrafish may become
active only after gastrulation.
PrP-dependent influence of Aβ oligomers on zebrafish
embryonic SFKs and AJs
In mammalian neurons, binding of Aβ oligomers to
neuronal PrP activates Fyn and blocks the endocytosis of
the NR2B subunit of the NMDA receptor (NMDAR),
leading to glutamate excitotoxicity and synaptic damage
[7]. In our zebrafish embryos, PrP-mediated activation of
Fyn and Yes prevents the endocytosis of E-cadherin to
support embryonic cell adhesion. The obvious similarity
between these two unrelated events prompted us to ask
if Aβ oligomers would modulate zebrafish embryonic
SFKs and AJ components in a PrP-dependent manner.
As a negative control, we used monomeric Aβ, which
unlike oligomeric Aβ, does not induce Fyn activation
(Um et al, 2012). To facilitate access of Aβ to embryonic
cell surfaces, we dissociated 5 hpf zebrafish control and
PrP-1 morphant embryonic cells and allowed them to
re-aggregate for one hour in the presence or absence of
0.5 μM Aβ oligomers before analyzing them for changes
in the levels of SFKs and AJ components. Notably, Aβ
oligomers triggered increased levels of p-Tyr416 (acti-
vated) Src/Yes and Fyn (4.4-fold and 10.1-fold in-
crease, respectively; p < 0.001) without significantly
affecting their total levels (Fig. 8c-e). In addition, the levels
of E-cadherin and β-catenin were elevated by 2.6- and
2.2-fold, respectively (p < 0.001, Fig. 8a and b). The
increase in p-Tyr416 SFKs and β-catenin was
dependent on endogenous PrP-1 expression and Aβ
oligomerization, since it was observed neither in PrP-1
morphant cells nor upon exposure to Aβ monomers.
Interestingly, the increase in mature E-cadherin was also
PrP-1-dependent but it was indistinctively triggered by Aβ
monomers or oligomers (see Discussion). Thus, in zebra-
fish blastocytes, Aβ oligomers induce biochemical changes
consistent with a PrP gain-of-function scenario.
Discussion
Identifying conserved molecular pathways controlled by
PrPC in vivo is an important step towards understanding
mechanisms of neurodegeneration. Using multiple knock-
down and cross-rescue experiments, we define here a gen-
etic pathway in which SFKs act downstream of PrP-1 to
support embryonic AJ function. Although Fyn activation
by PrP is widely recognized, its physiological significance
(See figure on previous page.)
Fig. 7 Effect of Δ23-31 and ΔCR deletions on PrP activity. a. Mouse PrP deletion mutants. Protein domains are marked with different colors:
SP = signal peptide, R = repetitive domain, H = hydrophobic stretch, G = globular domain; green triangles = GPI-anchor. b. Detection of mouse WT
or mutant PrPs using the D18 anti-PrP antibody on 6 hpf embryo protein lysates. c. Phenotypic quantification of 7 hpf embryos co-injected with
PrP-1 morpholinos and PrP mRNAs. d. Localization of mouse PrP constructs in the deep cells of 6 hpf embryos (6H4 anti-PrP antibody staining).
Scale bar = 10 μm. e. Embryonic phenotypes upon expression of zebrafish (ZF) or mouse (mo) PrP mRNAs (7 hpf, lateral views); arrowheads show
abnormal dorsal thickening; V = ventral, D = dorsal. f. Quantification of 7 hpf embryos with dorsoventral phenotypes upon expression of mouse
PrPs. Mean values are shown in (c) and (f). g. MTT viability assay of HEK cells expressing mouse or zebrafish PrPΔCRs after Zeocin treatment.
WB =Western blot; IF = immunofluorescence. Data are shown as the average percentage of A570 values in untreated cells ± SEM; statistical
significance was assessed using unpaired, two-tailed t-tests, * = p≤ 0.05, ** = p≤ 0.01
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had so far remained unclear. This notion can now be
extended to Yes, which we here identify as a previously
unknown effector of PrP in vivo. As with our findings in
zebrafish, synergistic contributions of SFKs to cell adhe-
sion are evident in Fyn/Src and Fyn/Yes knockout mice
[47]. Furthermore, single Fyn, Yes or Src knockouts ex-
hibit mild developmental phenotypes but double (Fyn/Src
or Src/Yes) and triple knockouts are embryonic lethal [48,
49]. The specific requirement of SFKs during gastrulation
is particularly evident in frogs and zebrafish [30, 50 and
this study]. Aside from these similarities across model or-
ganisms, differences are also apparent: Fyn/Yes knockout
mice undergo kidney degeneration but remain viable [49],
whereas Src is essential for epiboly in Xenopus but
not in zebrafish [30, 50]. Our data on PrP, Fyn and
Yes suggest that PrP utilizes multiple SFKs to modu-
late a wide spectrum of cellular responses. Hence, the
functional redundancy of SFKs and the diversity of
their downstream targets might explain the differences be-
tween the PrP loss-of-function phenotypes of mice and
zebrafish [13].
Both our gain- and loss-of-function data indicate that
PrP-1 positively regulates Fyn and Yes activity. Does this
imply that PrP can directly activate SFKs? To our know-
ledge, PrP has neither kinase nor phosphatase activities.
Moreover, it is not clear whether the GPI-anchor of PrP
can extend across the plasma membrane and interact
with cytoplasmic SFKs. Nevertheless, clustering of PrP
at cell-cell contacts can induce coalescence and cross-
activation of SFK molecules, or their activation by PrP-
associated, tissue-specific trans-membrane proteins like
N-CAM or mGluR5 [29, 51]. In addition, the GPI-
anchor of PrP influences its interaction with signaling
complexes by determining its localization within distinct
membrane microdomains [52]. Particularly relevant to
our findings is the modulation of SFKs through the pref-
erential degradation of their activated (p-Tyr416) forms
via lysosomal pathways [53]. In fact, activated SFKs were
reduced in PrP-1 morphants and this effect partially re-
quired lysosomal function. Moreover, it was recently
shown that the degradation of activated SFKs can switch
from proteasomal to autophagic/lysosomal when a key
stimulus such as focal adhesion kinase (FAK)-signaling
is absent [54]. Similarly, the loss of PrP-1 could direct acti-
vated SFKs to a lysosomal degradation pathway. Thus,
PrP-1 supports SFK function either by inducing their
activation and/or by eliciting a signal that inhibits the deg-
radation of their activated forms.
Because PrP enhances the levels and plasma mem-
brane localization of E-cadherin and β-catenin via SFKs,
our data also offer mechanistic insights into poorly under-
stood aspects of AJ regulation. For instance, while classical
studies in oncogene-transformed cells found that SFK
activity disrupts AJs, more recent reports indicate the
opposite. This contradiction has been explained through a
“bimodal” model in which SFKs promote cell adhesion at
low, physiological levels but suppress it at high, oncogenic
Fig. 8 Aβ oligomers induce a PrP gain-of-function effect in zebrafish
embryonic cells. Levels of AJ proteins (a and b) and SFKs (c-e) in 6
hpf embryonic cells upon treatment with Aβ monomers (m) or
oligomers (o). Actin was used as a protein loading control (f).
E-cadherin arrowheads as in Fig. 1; arrows = distinct SFKs bands
(black: Src/Yes; grey: Fyn). Densitometric analysis of Western blot
bands is shown in arbitrary units (AU). Data were collected from
three independent experiments (average values ± SEM); statistical
significance was assessed using unpaired, two-tailed t-tests,
* = p≤ 0.05, *** = p≤ 0.001
Sempou et al. Molecular Neurodegeneration 2016, 10: Page 12 of 19
http://www.molecularneurodegeneration.com/content/10/1/
levels [33]. The positive regulation of AJs by SFKs in
zebrafish (this study) and Drosophila embryos [55] pro-
vides in vivo support for this model. On the other hand, it
is widely recognized that Tyr phosphorylation of β-
catenin by SFKs promotes AJ disassembly [56]. How could
the same phosphorylation events have positive and nega-
tive effects on AJs? In our analyses, β-catenin Tyr142 was
indeed phosphorylated by SFKs but increased pTyr142
levels did not result in the loss of cell adhesion. Therefore,
similar to [47, 57], our experiments suggest that Tyr
phosphorylation of β-catenin is not the predominant
event leading to the disruption of AJs under physiological
conditions.
Importantly, SFKs also phosphorylate E-cadherin and
modify its accessibility to binding partners that compete
to promote or prevent its retention at the plasma mem-
brane. Of key relevance among these molecules are AP-
2 -a clathrin-associated mediator of endocytosis- and
p120, which protects E-cadherin from AP-2 binding and
Hakai-mediated ubiquitination [58]. Our finding that
SFK activity prevents the clathrin-dependent endocytosis
and degradation of E-cadherin is consistent with this
mechanism and suggests that the regulation of E-cadherin
endocytosis overrides the effect of β-catenin (Tyr) phos-
phorylation on AJ stability. Along the same lines, blocking
E-cadherin endocytosis in PrP-1 morphants restored the
plasma membrane association of β-catenin, whereas pre-
venting β-catenin degradation did not rescue E-cadherin
levels. These data further suggest that increased E-
cadherin endocytosis precedes and drives β-catenin in-
ternalization upon PrP-1 knockdown. Since key regulators
of AJ turnover like AP-2, Hakai, p120 and protein tyrosine
phosphatases (PTPs) are themselves targets of SFKs, more
complex regulatory scenarios cannot be excluded at this
time.
Consistent with our PrP-1 knockdown data, PrP over-
expression induced a lethal gastrulation phenotype by
enhancing SFK activity and E-cadherin cell surface expres-
sion. This accounts for the increased Ca+2-dependent ag-
gregation observed in PrP-OE embryos [21], as well as for
their morphogenetic defects and death by mechanical dis-
ruption. Unexpectedly, β-catenin is not up-regulated along
with E-cadherin in these embryos but instead its early role
as a dorsalizing signal becomes lessened. Its increased cell
surface localization and reduced levels in mid-blastula
dorsal nuclei agree with the reported ability of E-cadherin
to sequester β-catenin at the plasma membrane [27]. A
similar phenomenon is known in Xenopus and Drosophila
embryos, where E-cadherin up-regulation antagonizes
β-catenin signaling [59–61]. Interestingly, β-catenin can
promote its own transcription [62, 63], suggesting that its
reduction in the dorsal nuclei of 3 hpf PrP-OE embryos
might impair its local biosynthesis. Accordingly, dorsal β-
catenin is down-regulated by 6 hpf and this effect is not
due to protein degradation. Although no specific anti-
bodies are available to distinguish between the two zebra-
fish β-catenins (β-catenin-1 and -2), our data suggest that
PrP modifies the function of at least β-catenin-2, as only
this duplicate has dorsalizing activity [64].
Canonical Wnts promote β-catenin signaling by pre-
venting the degradation of its cytosolic pool [56]. In con-
trast, PrP overexpression inhibits β-catenin signaling by
stabilizing it at the plasma membrane. This might sug-
gest that PrP antagonizes Wnts in dorsal marginal cells
of the blastula. However, the two pathways likely act
independently because β-catenin degradation is neither
increased in PrP-OE embryos nor reduced in PrP-1 mor-
phants. In addition, mutants of the zebrafish dorsalizing
gene Wnt8 exhibit a different dorsoventral phenotype
with no defects in cell adhesion [65]. Interestingly, a
modulatory effect of PrP on Wnt signaling may depend
on its sub-cellular localization. For instance, in the nu-
cleus of intestinal epithelial cells, PrP can interact with
β-catenin and promote the transcription of Wnt-target
genes [66]. Such a mechanism was not evident in our
overexpression experiments and may therefore be re-
stricted to differentiated cell types with significant levels
of PrP and β-catenin in the nucleus. Given the promin-
ent role of Wnt signals in cancer and neurodegenera-
tion, it will be of interest to explore additional regulatory
interactions between PrP and Wnt across cell types and
tissues.
The ability of mouse PrP to modulate SFKs and AJs in
the zebrafish gastrula is greatly enhanced by residues
23-31, which also control neuronal survival and neuro-
toxicity in transgenic mice [43–45]. Could such dissimilar
activities of PrP have a common regulatory basis? The 23-
31 equivalent regions of mouse and zebrafish have low
amino acid sequence identity. However, their conserved
basic character suggests that positive charge is key to their
function. In fact, N-terminal polybasic regions can greatly
enhance the plasma membrane association of many pro-
teins via electrostatic interactions with membrane lipids.
As demonstrated for Gα subunits, the ensuing lateral
segregation within plasma membrane sub-regions has a
profound effect on the molecule’s signaling properties
[67]. Along these lines, we have proposed that the polyba-
sic N-terminus of PrP allows its insertion into the plasma
membrane [43]. Therefore, the 23-31 region of PrP could
indirectly facilitate its interaction with distinct functional
partners located at special microdomains of the plasma
membrane.
PrPΔCR neurotoxicity in mice has been attributed to a
disrupted interaction between the CR and a hypothetical
neuroprotective partner [42]. The effect of zebrafish
PrPΔCRs on HEK cell viability (this study) implies that
this phenomenon is conserved across vertebrate PrPs.
Yet, no ΔCR-associated lethality was evident in zebrafish
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gastrulae, suggesting that the relevant cytotoxic mol-
ecule is absent in early embryonic cells. Accordingly,
PrPΔCR causes toxicity in neurons only upon exposure
to glutamate or cationic drugs [68]. Moreover, ΔCR
transgenic mice become ill only one week after birth
[42]. Therefore, a related effect in fish may be restricted
to neuronal cell types at later developmental stages and/or
require induction by additional factors.
The WT-like activity of the ΔCR construct in our as-
says shows that the CR is not essential for embryonic
PrP function. Nevertheless, the ability of PrPΔCR to in-
duce spontaneous ionic currents in cultured cells [69]
adds to increasing evidence showing that PrP can influ-
ence ion channel function at neuronal plasma membranes
[70, 71]. Given the known role of SFKs as modulators of
synaptic ion channel activity [13, 72], the PrP/SFK path-
way described here provides a testable molecular hypoth-
esis linking PrP dysfunction, abnormal SFK activity and
downstream alterations in synaptic physiology.
Remarkably, nanomolar concentrations of human Aβ
oligomers activate the PrP/SFK cascade both in mamma-
lian neurons [7] and zebrafish embryonic cells (this study),
leading to increased NMDAR or AJ stability at the plasma
membrane, respectively. The similarity between these
findings extends beyond the common involvement of PrP
and SFKs. Although structurally and functionally un-
related, NR2B and E-cadherin are membrane proteins
whose endocytic trafficking is negatively modulated by
Tyr phosphorylation. The existence of a molecular mech-
anism able to control both cell adhesion and synaptic
transmission has interesting implications for neurodegen-
eration, as cadherin adhesive complexes play critical roles
in synapse formation and plasticity [73], and their inhib-
ition accelerates Aβ-induced synaptic damage [74]. Our
data suggest that PrP/SFK-mediated dysregulation of cad-
herins and NMDARs jointly contribute to Aβ-induced
synaptic failure. This is an interesting scenario that can
now be experimentally addressed in Alzheimer’s research
models.
In line with the study by Um and colleagues [7], we
did not observe SFK activation by Aβ monomers. The
reason for this might be stoichiometric: an Aβ oligomer
-containing up to 100 monomeres [75]- is likely to bind
more PrP molecules than a monomer and induce the
amount of PrP clustering required for SFK activation.
Nonetheless, Aβ monomers did up-regulate E-cadherin
in an SFK-independent manner, suggesting that Aβ mono-
mers and oligomers activate mutually exclusive pathways
that converge in the modulation of E-cadherin expression.
Among the molecules that could mediate the effect of
Aβ monomers on E-cadherin, receptor tyrosine kinases
(RTKs) are particularly interesting. Many RTKs localize to
AJs; some -like the epidermal growth factor receptor
(EGFR)- can phosphorylate cadherin/catenin complexes
independently of SFKs [76] and interact with PrP [77].
Moreover, the insulin-like growth factor-1 receptor (IGF-
1R) mediates a neuroprotective activity of Aβ monomers
[78], binds and modulates E-cadherin [79], and is ex-
pressed in the zebrafish gastrula [80]. Therefore, our re-
sults support the view that Aβ monomers exert biological
activities distinct from those of Aβ oligomers [81]. The
ability of the Aβ peptide to interact with any given partner
(PrP or RTKs) probably depends on its aggregation state,
as oligomerization causes its C-terminal half to assume a
unique conformation that masks some of its amino acid
side chains and creates new epitopes from its polypeptide
backbone [82–84]. On the other hand, the biochemical
changes induced by human Aβ peptides in zebrafish cells
strongly suggest that the Aβ-binding sites of PrP are
evolutionarily conserved structures. In fact, zebrafish
PrPs contain positively charged regions similar to those
identified as the two major Aβ-binding sites of mamma-
lian PrPs [75, 85].
Altogether, our work lays out a mechanistic framework
in a simple model organism to explore the physiological
complexity of PrP-associated signals, their connection to
protein aggregation diseases, and their potential use in the
identification of novel therapeutic targets and compounds.
Conclusions
The present study combines genetic, biochemical and
cell biological approaches in zebrafish embryos to ex-
plore the physiological significance of PrP signaling and
expand our knowledge about the regulation of SFKs and
AJ components during gastrulation. In particular, we
show that: 1) PrP activates not only Fyn but also the
related SFK member Yes, and that it preferentially
controls the degradation of their activated forms; 2) Fyn
and Yes positively regulate E-cadherin by preventing its
endocytosis and degradation; 3) Tyrosine phosphoryl-
ation of β-catenin is not the predominant event leading
to AJ disruption; 4) PrP-mediated control of the SFK/AJ
pathway requires the same N-terminal stretch needed
for its neuroprotective activity; 5) Exposure to Aβ oligo-
mers overactivates the SFK/AJ pathway in a PrP-dependent
manner.
This early developmental mechanism is also relevant
to the study of PrP pathogenesis, as it provides us with a
simple experimental system to monitor the cellular events
impaired by mammalian neurotoxic PrP mutants in vivo.
The fact that Aβ oligomers trigger PrP-dependent changes
not only in Fyn but also in Yes function suggests that mul-
tiple SFKs and their diverse cellular targets are common
players in prion and Alzheimer’s pathologies. Further-
more, our observations relate to key oncogenic path-
ways because they illustrate how SFKs regulate AJs under
physiological conditions. On the other hand, the similar
control of E-cadherin and NMDAR endocytosis via PrP-
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and SFK-dependent tyrosine phosphorylation suggests a
general role of PrP in controlling the stability of membrane
proteins in diverse physiological scenarios. Altogether, our
findings highlight the zebrafish as a powerful tool to dissect
the complex roles of PrP in physiology and disease as well
as to facilitate drug discovery efforts.
Methods
Zebrafish
Wild-type (WT) zebrafish were kept at the University of
Konstanz's animal facility following standard procedures
[86]. Embryos were raised and staged as described previ-
ously [21].
Molecular cloning
Plasmids encoding zebrafish WT Fyn and Yes cDNAs, a
kind gift of Dr. Jeroen den Hertog, were used to create C-
terminally tagged EGFP fusion constructs. The following
PCR primers (Eurofins MWG Operon) were designed to
remove stop codons: Fyn-F-(EcoRI): 5′-CGAATTCAT




GGCTGATA-3′. Constitutively active (CA) forms were
generated by mutating Tyr residues 531 in Fyn and 540 in
Yes to Phe using instead the following reverse primers:
Fyn CA-R-(ApaI): 5′-GGGGCCCAGAGGTTGTCCCCG
GGTTGGAAC-3′ and Yes CA-R-(ApaI): 5′-GGGGCCC
ACAGGTTGTCTCCGGGCTGAAAC-3′. PCR products
were cloned into pCRII-TOPO (Invitrogen), digested with
EcoRI/ApaI and subcloned into pEGFP-N1 (Clontech).
For expression in zebrafish embryos, inserts lacking 9 bp
upstream of the EGFP stop codon were excised with
EcoRI/BsrGI, and inserted into the corresponding sites of
pCS2 + -EGFP, thereby restoring the full-length fusion
constructs. pCS2 + -EGFP was constructed by inserting
EGFP into the EcoRI/XbaI sites of pCS2+. Mouse PrP
cDNAs containing the 3 F4 epitope were excised from
pcDNA3 and inserted into pCS2+ at the following sites:
HindIII/BamHI for WT, ΔCR and Δ23-31/ΔCR PrP, and
HindIII/XhoI for Δ23-31 PrP. The missing 92 bp fragment
of pCS2+ downstream of the HindIII site (containing the
SP6 promoter) was re-introduced using the cloning oligos
SalI/HindIII-oligo 1: 5′-TCGACgatttaggtgacactatagaatacaa
gctacttgttctttttgcaagctaaatccactgtgatatcttatgttcgatgaacaaga
aaaacgtTTCGA-3′ and SalI/HindIII-oligo-2: 5′-AGCT
TtgcaaaaagaacaagtagcttgtattctatagtgtcacctaaatcG-3′ (Euro-
fins MWG Operon). Oligos were annealed for 10 min at
50 °C and the resulting fragment was inserted into
pCS2+ at the SalI/HindIII sites. Zebrafish ΔCR PrPs
were generated by deleting amino acids 374-393 (GFGK
KAVVAAGVGAMAGMAI) in PrP-1 and 295-314 (GFGK
QAIIAAGAGAVAGMAL) in PrP-2 via inverse PCR.
The corresponding WT cDNAs in pCS2+ were used
as templates with the following primer combinations:
PrP-1-ΔCR-Fwd: 5′- pGGCTATGGAATAGGAAACTT
TCAACG -3′/PrP-1-ΔCR-Rev: 5′- pTTTGGATTTTG
CAGAAGGGTTGTAGC -3′, and PrP-2-ΔCR-Fwd: 5′-
pGGATATGGCCTGGGAAGTTTCCCCCG -3′/PrP-2-
ΔCR-Rev: 5′- pCTTTGATTTGTAAGAAGGGGCCA
TAC -3′. PCR products were blunt end ligated to generate
circular DNA.
Morpholino and mRNA injections
Lissamine-tagged, non-overlapping morpholinos against
PrP-1 were described earlier [21]: MO-PrP1-1: 5′-
GGTCCATAAAAAGGTTGAAGAAGCG-3′ and MO-
PrP1-2: 5′-TCTCTCCCGCAGCACTCTCTGCTCA-3′.
Similarly designed morpholinos against zebrafish Fyn
and Yes [30] were purchased from Gene Tools (Oregon):
Fyn: 5′-TGTCCTTACATTGCACACAGCCCAT-3′ and
Yes: 5′-CCTCTTTACTCTTGACACAGCCCAT-3′. Mor-
pholinos were microinjected at 0.5 ng/nl (PrP-1-1 and -2,
each) and 1.6 ng/nl (Fyn and/or Yes, each) in 1X Danieau
buffer/0.125 % Phenol Red (Sigma). Capped mRNAs were
synthesized in vitro using the mMessage mMachine SP6
kit (Ambion). For comparable levels of PrP overexpres-
sion, mRNAs were microinjected in 0.05 M KCl/0.125 %
Phenol Red at 40 ng/μl (WT PrP), 30 ng/μl (ΔCR and
Δ23-31 PrP) and 20 ng/μl (Δ23-31/ΔCR PrP and PrP-1).
For PrP rescue or hypomorph experiments, mRNAs were
co-injected at half the above concentrations. For Fyn and
Yes rescue experiments, mRNAs were co-injected with
morpholinos at 11 pg/nl (WT) and 1 pg/nl (CA), each.
Microinjections were carried out at the one- to-four-cell
stage using an injection volume of 5 nl per embryo. For
phenotypic analyses, at least 200 embryos per experiment
were examined in three independent experiments.
Average numbers of embryos with a given phenotype
are given as the percentage of total embryos treated,
and statistically validated with two-tailed unpaired t-tests.
Images of live embryos were acquired with a LUMAR.V12
microscope (Zeiss) and processed using Axiovision
and Adobe Photoshop CS5.
Chemical inhibitors
Pharmacological inhibitors were co-injected with mor-
pholinos or mRNAs at 100 μM (chloroquine, Sigma),
50 mM (ammonium chloride, Calbiochem), 10 μM (MG-
132, Calbiochem) in 0.05 % DMSO; 10 or 50 μM
(Dynasore, Calbiochem) in 0.1 % or 0.02 % DMSO,
respectively; and 5 μM (PP2 or PP3) in 0.05 % DMSO; all
final concentrations.
Immunofluorescence
Embryos were stained as described previously [21]. The
following primary antibodies were used: mouse monoclonal
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anti E-cadherin (BD Biosciences, 1:250), anti β-catenin (BD
Biosciences, 1:250), anti-phosphotyrosine (Cell Signaling,
1:500), anti-PrP 6H4 (Prionics, Switzerland); rabbit poly-
clonal anti β-catenin (Sigma, 1:500) and anti-Src (Cell
Signaling, diluted 1:100). Secondary antibodies: Alexa-
488 conjugated goat anti-rabbit or -mouse and Cy3-
conjugated donkey anti-rabbit or -mouse (Jackson Immu-
noresearch, 1:1000), Cy5 conjugated goat anti-rabbit or
-mouse (Invitrogen, 1:1000). Whole embryos were imaged
as flat (deyolked) or thick (with yolk) mounts on LSM 510
and 710 confocal microscopes (Zeiss), and images were
further processed using Adobe Photoshop CS5. Differ-
ences in protein distribution along embryonic axes were
visualized using fluorescence profiles generated with LSM
510 and ZEN software (Zeiss). To study β-catenin trans-
location, Z-sections of whole embryos were generated and
marginal cells with nuclear β-catenin were counted. To
determine ratios of plasma membrane vs. cytosolic β-
catenin in dorsal blastomeres, whole cell/cytoplasm areas
were outlined and the corresponding fluorescence (inte-
grated densities) measured and subtracted using Image J.
Western blot
Embryos were dechorionated in 1 mg/ml Pronase
(Sigma) for 10 min at 30 °C, washed four times in 30 %
Danieau buffer, and mechanically dissociated in deyolk-
ing and wash buffer as previously described [87]. The
dissociated embryonic cells were disrupted in ice-cold
lysis buffer (20 mM Tris–HCl, pH 7.5, 2 mM EDTA,
100 mM NaCl, 5 mM MgCl2, 1 % Triton X-100, 10 %
glycerol) supplemented with 1X Halt Protease and Phos-
phatase Inhibitor Cocktail (Thermo Scientific). Protein
concentrations were determined using the Bradford
Assay (Sigma), and 17 μg of lysate per lane (approxi-
mately ten 6-hpf embryos) were loaded onto 10 % or
12 % SDS gels. For improved detection of E-cadherin
isoforms, embryos were dissociated on ice and directly
lysed in SDS loading buffer. The following primary anti-
bodies were diluted in TBS-0.1 % Tween containing 3 %
bovine serum albumin (Sigma Aldrich): mouse mono-
clonal anti-E-cadherin (BD Biosciences, 1:1000), anti-
β-catenin (BD Biosciences, 1:1000), Prion (3F4) antibody
(Covance); rabbit polyclonal anti-phospho-β-catenin
Y142 (1:500), anti-δ-catenin (1:1000), anti-α-tubulin
(1:5000) from Abcam, and anti-Src (1:1000), anti-
phospho-Src Y416 (1:500), anti-phospho-Src Y527
(1:500) from Cell Signaling; goat polyclonal anti-Actin
(Santa Cruz Biotechnology, 1:1000). The specificity of
commercial antibodies on total and phosphorylated
zebrafish proteins was carefully assessed through compari-
son of fish and mammalian amino acid target epitopes,
preliminary Western blots and immunofluorescence
controls, as well as experiments published by us and
colleagues [21, 34, 38]. Secondary, HRP-conjugated
antibodies: rabbit polyclonal goat anti-rabbit or rabbit
anti-goat IgG (H+ L) (Jackson Immunoresearch, 1:10000);
goat polyclonal anti-mouse IgG (H + L) (Invitrogen,
1:5000) and anti-human IgG (Sigma Aldrich, 1:10000). The
anti-PrP hybridoma D18 was provided by Dennis R.
Burton (The Scripps Research Institute, La Jolla, CA);
the purified antibody was used at 0.5 μg/ml. The in-
tensity of Western blot signals was quantified using Ima-
geJ and statistically evaluated using Excel and Graphpad
Prism 6.0d.
Drug-based cellular assay (DBCA)
HEK293 (ATCC CRL-1573) cell culture conditions, the
DBCA, and MTT assay have been described previously
[46]. Cells were plated at 70 % confluency, transfected
for 6 h with Lipofectamine 2000 (Invitrogen), and fur-
ther incubated for 18 h before treatment with 0.5 mg/ml
Zeocin for 24 h at 37 °C.
Aβ treatment
Embryos were dissociated at 5 hpf as described above and
cells were incubated for 1 h at 28.5 °C in 30 % Danieau
medium containing 0.5 μM monomeric or oligomeric Aβ.
Aβ oligomers were prepared as reported previously [88].
Cell lyses and WB analyses were performed as described
above.
Additional files
Additional file 1: Figure S1. Recovery of epiboly in PrP-1 morphants
by treatment with degradation and endocytosis inhibitors. A. Treatment
of PrP-1 morphants with DMSO alone does not restore epiboly. B. Treatment
with protein degradation inhibitors restores AJ components at the plasma
membrane of PrP-1 morphants (only MG-132 shown). Immunofluorescence
(IF) analysis of E-cadherin and β-catenin in the deep cell layer of 6 hpf embryos.
Scale bar = 10 μM. Figure S2. Fyn and Yes act downstream of PrP-1 during
epiboly. A. Immunofluorescence (IF) of E-cadherin and β-catenin in 6 hpf
Fyn and Yes single knockdown embryos. Scale bar = 10 μM. B. Photos of live
embryos at 6 hpf displaying normal or arrested epiboly. Recovery of epiboly
is visible in PrP-1 morphants expressing EGFP-tagged WT or CA Fyn and
Yes. Lissamine (Lis)-tagged PrP-1 morpholinos were used. Figure S3.
Changes in levels of total or phosphorylated SFKs, and phospho-tyrosine
upon PrP-1 knockdown. A. SFK levels in 6 hpf embryos (WB) after injection with
increasing PrP-1 morpholino doses. B. Changes in relative p-Tyr527 levels in
PrP-1 morphants, as measured by densitometric analysis of WB bands. WB for
total or p-Tyr527 SFKs was performed with 6 hpf embryo extracts. Values for
phospho Y527 SFKs were normalized to those of total SFKs. Average values ±
SEM of three independent experiments are depicted. C. Immunofluorescence
of total phosphorylated tyrosine in deep and EVL cells in 6 hpf embryos. Scale
bar = 10 μM. Figure S4. Sequence comparison of mouse and zebrafish
N-terminal polybasic and central regions (CR). A. Basic residues are marked
in turquoise and gray boxes indicate repetitive domains. B. Boxed areas
indicate the CRs. Hydrophobic domains are marked in red. Figure S5.
Effects of embryonic PrP OE on the localization of SFKs and AJ components.
A. Immunofluorescence in dorsal deep cells of 6 hpf embryos
(animal views); arrowheads point at plasma membrane localization; scale
bar = 10 μM. B. Gastrula midsections of 6 hpf ZF PrP-1 overexpressing
embryos, immunostained as indicated and shown from lateral or animal
perspectives. Graphs present fluorescence profiles along the ventral-dorsal
axis (indicated by red arrows; V = ventral, D = dorsal). C. Blastula midsections
of 3 hpf embryos (two different planes from animal view), immunostained
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as indicated; arrowheads point at areas of increased immunofluorescence.
Figure S6. Changes in Src activation and localization upon expression of
mouse and zebrafish PrPs in MCF-7 cells. A. WB analysis with lysates of
MCF-7 cells expressing EGFP-tagged PrPs. B. Subcellular distribution of
EGFP-PrPs and Src immunofluorescence in MCF-7 cells. Scale bar = 10 μM.
C. Quantification of Src immunofluorescence at cell-cell contact sites. Graph
depicts percentages of cells (average values ± SEM) with different percentage
of Src at cell-cell contact sites. Values were normalized to whole cell Src
immunofluorescence. Figure S7. Quantification of cells with nuclear
β-catenin in 3 hpf embryos expressing various PrP constructs. Average
numbers of cells with nuclear β-catenin per embryo ± SEM are shown
(n = 10, three independent experiments). (DOCX 3704 kb)
Additional file 2: Video S1. PrP OE induces a lethal gastrulation
phenotype characterized by mechanical disruption. Time-lapse recording
between 6 and 9 hpf. Control embryo (left), PrP-1 morphant embryo
(center), and embryo overexpressing mouse PrP (right). (MOV 11369 kb)
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